Vagal afferents, the area postrema, and the anatomy of nausea
A tour of the tissues where the receptor is expressed, and what happens in each.
Dosing
Page 16 of 31 of this archive, newest first.
Pancreatitis, obstruction, gallbladder: three things nausea can be
A small number of serious gastrointestinal events occur in people taking these drugs. Distinguishing them from the expected effect profile is the most consequential…
The GLP-1 receptor is not a switch, and survodutide is not a key
What the in-vitro data supports, what it does not, and where the extrapolation to a person begins.
The incretin receptors, ranked by how much we actually know about them
Selectivity, potency and efficacy are three different measurements. The trade routinely reports none of them.
The upper rungs, ranked by evidence
Where the curve flattens, what flattens with it, and what does not.
India pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The interventions with trial support, and the much longer list without
We separate what is supported, what is reasonable, and what is folklore, and we do not pretend the boundaries are crisp.
Argentina pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
How much water: the question with no single right answer
The diluent choice affects preservation and in-use period rather than the arithmetic — but the wrong choice for a multi-dose vial is a sterility decision, not a convenience…
What the new Spain guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The lowest effective dose is a real concept with almost no data behind it
A survey of the maintenance evidence, which is shorter than the survey of the withdrawal evidence.
What the new Singapore guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the pharmacokinetics permit and what they cannot tell you
A great deal of practice has grown up around intermittent schedules. The randomised evidence for any of them is, as far as the Journal can establish, nil.
Three weeks off is a fresh start, whether or not you want one
Concentrations fall by half a week, so a month away leaves a small fraction of steady state. Resuming at the previous dose presents the receptor with a step it has not seen…
Vagal afferents, the area postrema, and the anatomy of nausea
A tour of the tissues where the receptor is expressed, and what happens in each.
Brazil pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The limits of mechanism: why receptor data will not tell you who responds
Receptor pharmacology is strong on average effects and almost silent on individual variation. That gap is where most reader questions live.
Mapping a rotation that you will actually follow
Repeated injection into the same small area produces lipohypertrophy — thickened, rubbery subcutaneous tissue with blunted and erratic absorption. It is common, it is…
The steps get smaller as the ladder gets higher, and that is deliberate
What the published pharmacokinetics permit, what the labels state, and where the two diverge.
Three receptors, one peptide: the design problem behind triple agonism
Head-to-head data exists for some of these comparisons and not for others. This piece says which.